Constellation Pharmaceuticals, Inc. Banner Image

Constellation Pharmaceuticals, Inc. has reached its limit for free report views

Work for Constellation Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Constellation Pharmaceuticals, Inc.

  • Ticker CNST
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Constellation Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in drivingMore disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals, Inc.

Most Recent Annual Report

Constellation Pharmaceuticals, Inc.
MOST RECENT 2021 Form 10K, 2020 Annual Report

Report Locked. Constellation Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports